Possible role for chlorpheniramine in the treatment of l-DOPA induced dyskinesia in Parkinson’s disease
- 55 Downloads
Dopamine (DA) replacement therapy with l-3,4-dihydroxyphenylalanine (l-DOPA) remains the most effective medication for the symptomatic relief of Parkinson’s disease (PD). However, chronic l-DOPA treatment is often complicated by a variety of involuntary movements, termed l-DOPA-induced dyskinesia (LID), which represents one of the major limitations in the treatment for PD. Depending on clinical presentation and chronology after a dose of l-DOPA, LID can be classified in peak-dose, diphasic, and off period dyskinesias. Peak-dose dyskinesia occurs at the time of the highest brain concentration of l-DOPA and represents the most common type of LID. The current pharmacological treatment of this form of dyskinesia involves, as a first measure, the reduction of individual l-DOPA doses, which indeed can lead to improvement of dyskinesia, exacerbating however the symptoms of the disease. Slow-release l-DOPA preparations or spreading of the daily dose of L-DOPA into smaller but...
KeywordsChlorpheniramine l-DOPA Parkinson’s disease Pharmacotherapy
- 1.Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M. Activation of 5-HT(1A) but not 5-HT-(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 2001;76:1346–53.PubMedCrossRefGoogle Scholar